BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
0.437
-0.016 (-3.44%)
Nov 7, 2024, 3:25 PM EST - Market open
BioLineRx Revenue
BioLineRx had revenue of $5.39M in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $17.05M. In the year 2023, BioLineRx had annual revenue of $4.80M.
Revenue (ttm)
$17.05M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
$215,797
Employees
79
Market Cap
39.47M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CareCloud | 111.75M |
Verrica Pharmaceuticals | 9.21M |
SAB Biotherapeutics | 2.78M |
Lexaria Bioscience | 411.02K |
Adagio Medical Holdings | 399.00K |
BLRX News
- 2 days ago - BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 - PRNewsWire
- 22 days ago - BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide - PRNewsWire
- 7 weeks ago - BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection - PRNewsWire
- 3 months ago - BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates - PRNewsWire
- 3 months ago - BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 - PRNewsWire
- 5 months ago - BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) - PRNewsWire
- 5 months ago - BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript - Seeking Alpha